Conecte-se

Bibliografias temáticas / Methotrexate Toxicology / Artigos de revistas

Siga este link para ver outros tipos de publicações sobre o tema: Methotrexate Toxicology.

Artigos de revistas sobre o tema "Methotrexate Toxicology"

Autor: Grafiati

Publicado: 4 de junho de 2021

Última modificação: 1 de fevereiro de 2022

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Methotrexate Toxicology".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.

1

Slørdal, L., R. Jaeger, J. Kjaeve e J. Aarbakke. "Pharmacokinetics of 7-Hydroxy-methotrexate and Methotrexate in the Rat". Pharmacology & Toxicology 63, n.º 2 (agosto de 1988): 81–84. http://dx.doi.org/10.1111/j.1600-0773.1988.tb00915.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

UNDP/UNFPA/WHO/World Bank Special P. "Methotrexate for the termination of early pregnancy: a toxicology review". Reproductive Health Matters 5, n.º 9 (janeiro de 1997): 162–67. http://dx.doi.org/10.1016/s0968-8080(97)90020-3.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Armagan, A., E. Uzar, E. Uz, HR Yilmaz, S. Kutluhan, HR Koyuncuoglu, S. Soyupek, H. Cam e TA Serel. "Caffeic acid phenethyl ester modulates methotrexate-induced oxidative stress in testes of rat". Human & Experimental Toxicology 27, n.º 7 (julho de 2008): 547–52. http://dx.doi.org/10.1177/0960327108092293.

Texto completo da fonte

Resumo:

The aim of this study was to investigate the possible protective role of caffeic acid phenethyl ester on testicular toxicity of methotrexate in rats. Nineteen male rats were divided into three groups as follows: group I, control; group II, methotrexate-treated; group III, methotrexate + caffeic acid phenethyl ester-treated. In the second day of experiment, a single dose of methotrexate was intraperitoneally administered to groups II and III, although a daily single dose of caffeic acid phenethyl ester was intraperitoneally administered to group III for 7 days. At the end of the experiment, the testes of the animals were removed and weighed. In the tissue, the level of lipid peroxidation as malondialdehyde and activities of superoxide dismutase were higher in the methotrexate group than in the control group. Lipid peroxidation levels and superoxide dismutase activities were decreased in caffeic acid phenethyl ester + methotrexate group compared with methotrexate group. The activities of catalase in the methotrexate group decreased insignificantly although its activities were significantly increased by caffeic acid phenethyl ester administration. The activity of glutathione peroxidase did not change in the groups. There was significant difference in body weight between control and methotrexate-induced groups. In conclusion, the administration of methotrexate causes elevation of oxidative stress although treatment with caffeic acid phenethyl ester has protective effects on the oxidative stress in testes.

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Bardin, Philip G., David J. Fraenkel e Richard W. Beasley. "Methotrexate in Asthma". Drug Safety 9, n.º 3 (setembro de 1993): 151–55. http://dx.doi.org/10.2165/00002018-199309030-00002.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Gökçe, Ahmet, Suleyman Oktar, Ahmet Koc e Zafer Yonden. "Protective effects of thymoquinone against methotrexate-induced testicular injury". Human & Experimental Toxicology 30, n.º 8 (2 de setembro de 2010): 897–903. http://dx.doi.org/10.1177/0960327110382564.

Texto completo da fonte

Resumo:

Thymoquinone is the major active component derived from Nigella sativa. Methotrexate is a folic acid antagonist widely used in clinic. Aim of this study was to investigate the possible protective role of thymoquinone on testicular toxicity of methotrexate. Experiments were performed on male C57BL/6 mice (6 weeks old, 20 ± 2 g). The animals were divided into four groups with six mice in each group. Equivalent volumes of saline were injected intraperitoneally (i.p.) in the control group. In the thymoquinone group, mice received thymoquinone i.p. with a dose of 10 mg/kg/day for 4 days. Mice in the methotrexate group received single dose of methotrexate i.p., with a dose of 20 mg/kg. Finally, in the methotrexate plus thymoquinone group, in the first and the following 3 days after methotrexate administration, thymoquinone was injected with a dose of 10 mg/kg/day, i.p. At the end of the experiment, the left testis was quickly removed and divided into two parts for histological examination and biochemical analysis. Methotrexate alone increased total antioxidant capacity and myeloperoxidase activity compared to the controls. Thymoquinone treatment decreased total antioxidant capacity and prevented the increase in the myeloperoxidase activity. Light microscopy showed in mice that receiving methotrexate resulted in interstitial space dilatation, edema, severe disruption of the seminiferous epithelium and reduced diameter of the seminiferous tubules. Administration of thymoquinone reversed histological changes of methotrexate significantly. We suggest that thymoquinone use may decrease the destructive effects of methotrexate on testicular tissue of patients using this agent.

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Roy(Pal), Madhumita, Sharmila Sengupta, Rita Ghosh, Nitao P. Bhattacharyya, Subrata K. Dey e Sukhendu B. Bhattacharjee. "Characterisation of methotrexate-resistant clones". Mutation Research/Environmental Mutagenesis and Related Subjects 291, n.º 1 (fevereiro de 1993): 43–51. http://dx.doi.org/10.1016/0165-1161(93)90016-s.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Angelova, E., M. Krsnik-Rasol, M. Biruš e D. Papeš. "Methotrexate effects on plant cells". Mutation Research/Environmental Mutagenesis and Related Subjects 271, n.º 2 (1992): 148. http://dx.doi.org/10.1016/0165-1161(92)91162-k.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Raveendran, R., W. Heybroek, M. Caulfield, M. Lawson, S. M. L. Abrams, P. F. M. Wrigley, M. Slevin e P. Turner. "Indomethacin and Protein Binding of Methotrexate". Human & Experimental Toxicology 11, n.º 4 (julho de 1992): 291–93. http://dx.doi.org/10.1177/096032719201100411.

Texto completo da fonte

Resumo:

Indomethacin, a non-steroidal anti-inflammatory drug is known to increase the efficacy and toxicity of methotrexate, the widely used anti-cancer drug in man. The mechanism for this interaction has not been clearly established. However, since these drugs bind with albumin, a possible displacement of methotrexate by indomethacin from albumin might explain this interaction. To investigate the possible interaction an in-vitro protein-binding displacement study was carried out in 17 normal volunteers and in two groups of eight cancer patients. One group of patients had active disease and the other was in complete clinical remission. Serum samples were obtained and protein levels estimated. The protein binding of methotrexate was measured alone and with indomethacin using equilibrium dialysis. Statistical analysis of results suggested that the binding of methotrexate is not influenced by indomethacin, confirming that methotrexate is not displaced by indomethacin.

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

LoVecchio, Frank, Kenneth D. Katz, David J. Watts e Ian O. Wood. "Four-year experience with methotrexate exposures". Journal of Medical Toxicology 4, n.º 3 (setembro de 2008): 149–50. http://dx.doi.org/10.1007/bf03161192.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Stockley, Ivan H. "Methotrexate—NSAID interactions". Drug Intelligence & Clinical Pharmacy 21, n.º 6 (junho de 1987): 546. http://dx.doi.org/10.1177/106002808702100617.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Drafi, Frantisek, Katarina Bauerova, Viera Kuncirova, Silvester Ponist, Danica Mihalova, Tatiana Fedorova, Juraj Harmatha e Radomir Nosal. "Pharmacological influence on processes of adjuvant arthritis: effect of the combination of an antioxidant active substance with methotrexate". Interdisciplinary Toxicology 5, n.º 2 (9 de novembro de 2012): 84–91. http://dx.doi.org/10.2478/v10102-012-0015-4.

Texto completo da fonte

Resumo:

Abstract Oxygen metabolism has an important role in the pathogenesis of rheumatoid arthritis. A certain correlation was observed between oxidative stress, arthritis and the immune system. Reactive oxygen species produced in the course of cellular oxidative phosphorylation and by activated phagocytic cells during oxidative burst, exceed the physiological buffering capacity and result in oxidative stress. The excessive production of ROS can damage protein, lipids, nucleic acids, and matrix components. Patients with rheumatoid arthritis have an altered antioxidant defense capacity barrier. In the present study the effect of substances with antioxidative properties, i.e. pinosylvin and carnosine, was determined in monotherapy for the treatment of adjuvant arthritis (AA). Moreover carnosine was evaluated in combination therapy with methotrexate. Rats with AA were administered first pinosylvin (30 mg/kg body mass daily per os), second carnosine (150 mg/kg body mass daily per os) in monotherapy for a period of 28 days. Further, rats with AA were administered methotrexate (0.3 mg/kg body mass 2-times weekly per os), and a combination of methotrexate+carnosine, with the carnosine dose being the same as in the previous experiment. Parameters, i.e. changes in hind paw volume and arthritic score were determined in rats as indicators of destructive arthritis-associated clinical changes. Plasmatic levels of TBARS and lag time of Fe2+- induced lipid peroxidation (tau-FeLP) in plasma and brain were specified as markers of oxidation. Plasmatic level of CRP and activity of γ-glutamyltransferase (GGT) in spleen and joint were used as inflammation markers. In comparison to pinosylvin, administration of carnosine monotherapy led to a significant decrease in the majority of the parameters studied. In the combination treatment with methotrexate+carnosine most parameters monitored were improved more remarkably than by methotrexate alone. Carnosine can increase the disease-modifying effect of methotrexate treatment in rat AA.

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Giannini, Edward H., e James T. Cassidy. "Methotrexate in Juvenile Rheumatoid Arthritis". Drug Safety 9, n.º 5 (novembro de 1993): 325–39. http://dx.doi.org/10.2165/00002018-199309050-00002.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Bebarta, Vikhyat S., Matthew D. Hensley e Douglas J. Borys. "Acute Methotrexate Ingestions in Adults: A Report of Serious Clinical Effects and Treatments". Journal of Toxicology 2014 (2014): 1–5. http://dx.doi.org/10.1155/2014/214574.

Texto completo da fonte

Resumo:

Objective.Limited reported data have reports effects after acute ingestion of methotrexate. Treatment recommendations do not differentiate between exposure routes. Our objective was to determine the frequency of significant toxicity effects and use of therapy after methotrexate ingestion in adults.Methods.We performed a retrospective study on adult cases reported to 6 poison centers over 6 years (2000–2005) which exceed 180,000 exposures/year. Variables collected included demographics, dosages ingested, coingestions, clinical effects, and therapies with outcomes.Results.Sixty-three patients examined over the 6-year period met inclusion criteria. No patient in the series received dialysis or died. The mean dose ingested for all patients was 24 mg (range 2.5–100 mg) and the mean dose for suicidal ingestions was 47.5 mg (12.5–100 mg). The most common clinical effects were abdominal pain, oral irritation, throat irritation, nausea, dizziness, and headache. Nine patients received folinic acid and 3 patients received sodium bicarbonate. No patient developed renal failure, bone marrow suppression, seizure, or coma. No patient died or received dialysis.Conclusion.In our series of patients from 6 poison centers over six years, 63 cases of acute adult methotrexate ingestions were reported. Methotrexate toxicity from ingestion in adults was uncommon and rarely toxic.

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

CURD, CHERYL D., JOSEPH E. MANNO e JOHN J. STEWART. "Effects of Methotrexate on Intestinal Transit in Rats". Toxicological Sciences 5, n.º 5 (1985): 991–96. http://dx.doi.org/10.1093/toxsci/5.5.991.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Wolfgang, William J. "Exploring Protection from Methotrexate-Induced Teratogenicity in Flies". Toxicological Sciences 99, n.º 2 (outubro de 2007): 363–65. http://dx.doi.org/10.1093/toxsci/kfm198.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

CURD, C. "Effects of methotrexate on intestinal transit in rats". Fundamental and Applied Toxicology 5, n.º 5 (outubro de 1985): 991–96. http://dx.doi.org/10.1016/0272-0590(85)90181-2.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Remington, Helen St C., e Clifford C. Bailey. "Methotrexate Blood Level Monitoring". Drug Intelligence & Clinical Pharmacy 19, n.º 5 (maio de 1985): 372–73. http://dx.doi.org/10.1177/106002808501900508.

Texto completo da fonte

Resumo:

Methotrexate toxicity can be avoided following high-dose therapy if certain management procedures are adhered to. These include careful fluid balance management and therapeutic drug level monitoring. A case is reported of an episode of methotrexate toxicity resulting from a fluid balance problem.

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Severin, María J., Mara S. Trebucobich, Patricia Buszniez, Anabel Brandoni e Adriana M. Torres. "The urinary excretion of an organic anion transporter as an early biomarker of methotrexate-induced kidney injury". Toxicology Research 5, n.º 2 (2016): 530–38. http://dx.doi.org/10.1039/c5tx00436e.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Hendel, J., H. Poulsen, B. Nyfors e A. Nyfors. "Changes in Liver Histology during Methotrexate Therapy of Psoriasis Correlated to the Concentration of Methotrexate and Folate in Erythrocytes". Acta Pharmacologica et Toxicologica 56, n.º 4 (13 de março de 2009): 321–26. http://dx.doi.org/10.1111/j.1600-0773.1985.tb01297.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Verberne, Eline A., Emma de Haan, J. Peter van Tintelen, Dick Lindhout e Mieke M. van Haelst. "Fetal methotrexate syndrome: A systematic review of case reports". Reproductive Toxicology 87 (agosto de 2019): 125–39. http://dx.doi.org/10.1016/j.reprotox.2019.05.066.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Affleck, Joslynn G., e Virginia K. Walker. "Transgenic Rescue of Methotrexate-Induced Teratogenicity in Drosophila melanogaster". Toxicological Sciences 99, n.º 2 (22 de maio de 2007): 522–31. http://dx.doi.org/10.1093/toxsci/kfm123.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Chaudhary, Sushma, Manjul Pratap Singh, Chandana Venkateaswara Rao e Ajay Kumar Singh Rawat. "A Novel Natural Polymers Based Nanoparticles Gel Formulation for the Treatment of Rheumatoid Arthritis: Optimization and In-vivo Evaluation". Drug Delivery Letters 11, n.º 2 (28 de junho de 2021): 164–78. http://dx.doi.org/10.2174/2210303111666210219152401.

Texto completo da fonte

Resumo:

Background: In 1988, the US Food and Drug Administration permitted low dose methotrexate for the treatment of rheumatoid arthritis that would change the progression of the disease. Methotrexate is a folic acid antagonist and its systemic use causes numerous side effects; including hepatic toxicity. It would be preferable to deliver methotrexate by the topical route to reduce side-effects along with ease of administration and reduced dosing frequency. So, nanoparticle gel is a hopeful approach to treat rheumatoid arthritis. Objective: The study aims to develop a nanoparticles gel containing novel natural polymer-based methotrexate nanoparticles and evaluate its therapeutic potential on Complete Freund’s Adjuvant– Induced Arthritis rat model and compare it to methotrexate and dexamethasone gel. Materials and Methods: The five batches of methotrexate nanoparticles gel were prepared viz. F1W2, F2W2, F3W2, F4W2 and methotrexate gel for the topical application by using different concentrations of Carbopol 934 base and characterized for their evaluation parameters: homogeneity, grittiness, pH, spread-ability, viscosity determination, and drug content studies. The arthritic potential of methotrexate-nanoparticles gel was evaluated by Complete Freund’s Adjuvant–Induced Arthritis rats model based on percent inhibition oedema and arthritic score. Result and Discussion: Methotrexate nanoparticles gel significantly reduced the percentage inhibition of oedema compared to methotrexate and dexamethasone gel. The therapeutic activity of nanoparticles gel was found to be F3W2 ≥ F2W2 ≥ F1W2 ≥ F4W2 ≥ MTX gel. So, the optimized nanoparticle gel formulation F3W2 can be effective in the treatment of rheumatoid arthritis. Conclusion: The developed novel nanoparticles gel formulation can be a promising alternative to existing methotrexate and dexamethasone gel.

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Del Campo, Miguel, Kenjiro Kosaki, F. C. Bennett e Kenneth L. Jones. "Developmental delay in fetal aminopterin/methotrexate syndrome". Teratology 60, n.º 1 (julho de 1999): 10–12. http://dx.doi.org/10.1002/(sici)1096-9926(199907)60:1<10::aid-tera5>3.0.co;2-h.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Donnenfeld, Alan E., Anne Pastuszak, Jane Salkoff Noah, Betsy Schick, Nancy C. Rose e Gideon Koren. "Methotrexate exposure prior to and during pregnancy". Teratology 49, n.º 2 (fevereiro de 1994): 79–81. http://dx.doi.org/10.1002/tera.1420490202.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Schuurman, Henk-Jan, Harold T. Smith e Emanuele Cozzi. "Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates". Toxicology 213, n.º 1-2 (setembro de 2005): 1–12. http://dx.doi.org/10.1016/j.tox.2005.03.017.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Ezhilarasan, Devaraj. "Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms". Toxicology 458 (junho de 2021): 152840. http://dx.doi.org/10.1016/j.tox.2021.152840.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Vericat, J. E. Megías, S. Valero García, M. Amat Díaz, E. López Briz, M. N. Vila Clérigues e J. L. Poveda Andrés. "Stability of two methotrexate oral formulations". European Journal of Hospital Pharmacy 19, n.º 2 (12 de março de 2012): 150.1–150. http://dx.doi.org/10.1136/ejhpharm-2012-000074.173.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Benitez, B., E. Capilla, L. Gonzalez, M. P. Garcia de Miguel, C. Rueda, G. Casado, H. Varela, T. Roldan, M. Bravo e A. Herrero. "Carboxypeptidase rescue after high-dose methotrexate". European Journal of Hospital Pharmacy 19, n.º 2 (12 de março de 2012): 157.1–157. http://dx.doi.org/10.1136/ejhpharm-2012-000074.189.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

Bowen, Donnell, Terry J. Robbins e Robert M. White. "Interaction of 5?-deoxy-5-fluorouridine and methotrexate". Archives of Toxicology 63, n.º 5 (setembro de 1989): 401–5. http://dx.doi.org/10.1007/bf00303130.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

González‐Barón, M., M. P. Iniesta, M. I. Sanchez Reus e B. Ribas. "Anticarcinogenic methotrexate induces metallothionein synthesis†". Toxicological & Environmental Chemistry 13, n.º 3-4 (janeiro de 1987): 161–70. http://dx.doi.org/10.1080/02772248709357179.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Scanlon, Kevin J., Mohammed Kashani-Sabet, Arlene R. Cashmore, Michele Pallai, Barbara A. Moroson e Maria Saketos. "The role of methionine in methotrexate-sensitive and methotrexate-resistant mouse leukemia L1210 cells". Cancer Chemotherapy and Pharmacology 19, n.º 1 (fevereiro de 1987): 25–29. http://dx.doi.org/10.1007/bf00296250.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Bremnes, R. M., E. Smeland, N. E. Huseby, T. J. Eide e J. Aarbakke. "Acute Hepatotoxicity after High-Dose Methotrexate Administration to Rats". Pharmacology & Toxicology 69, n.º 2 (agosto de 1991): 132–39. http://dx.doi.org/10.1111/j.1600-0773.1991.tb01286.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Finkelstein, Y. "Emergency Treatment of Life-Threatening Intrathecal Methotrexate Overdose". NeuroToxicology 25, n.º 3 (março de 2004): 407–10. http://dx.doi.org/10.1016/j.neuro.2003.10.004.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Wheeler, Marsha, Patrick O'Meara e Michelle Stanford. "Fetal methotrexate and misoprostol exposure: The past revisited". Teratology 66, n.º 2 (22 de julho de 2002): 73–76. http://dx.doi.org/10.1002/tera.10052.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Bawle, E. V., J. V. Conard e L. Weiss. "Adult and two children with fetal methotrexate syndrome". Teratology 57, n.º 2 (fevereiro de 1998): 51–55. http://dx.doi.org/10.1002/(sici)1096-9926(199802)57:2<51::aid-tera2>3.0.co;2-9.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Finkelstein, Yoram, Shoshana Zevin, Bianca Raikhlin-Eisenkraft e Yedidia Bentur. "Intrathecal methotrexate neurotoxicity: clinical correlates and antidotal treatment". Environmental Toxicology and Pharmacology 19, n.º 3 (maio de 2005): 721–25. http://dx.doi.org/10.1016/j.etap.2004.12.031.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Yawata, Ayako, Saki Kimura, Misato Matsushita, Takehiro Mochizuki, Toshiyuki Chikuma, Hiroshi Hojo e Yasumitsu Ogra. "Cell-specific Synergic Effect of Cimicifugoside on Cytotoxicity of Methotrexate". JOURNAL OF HEALTH SCIENCE 57, n.º 4 (2011): 350–55. http://dx.doi.org/10.1248/jhs.57.350.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Martín, María Cecilia, Pablo Barbero, Boris Groisman, Miguel Ángel Aguirre e Gideon Koren. "Methotrexate embryopathy after exposure to low weekly doses in early pregnancy". Reproductive Toxicology 43 (janeiro de 2014): 26–29. http://dx.doi.org/10.1016/j.reprotox.2013.10.005.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Fuksa, Leos, Eva Brcakova, Gabriela Kolouchova, Petra Hirsova, Milos Hroch, Jolana Cermanova, Frantisek Staud e Stanislav Micuda. "Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats". Toxicology 267, n.º 1-3 (janeiro de 2010): 165–71. http://dx.doi.org/10.1016/j.tox.2009.11.010.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Wang, Xiuwei, Jianhua Wang, Tao Guan, Qian Xiang, Mingsheng Wang, Zhen Guan, Guannan Li et al. "Role of methotrexate exposure in apoptosis and proliferation during early neurulation". Journal of Applied Toxicology 34, n.º 8 (9 de julho de 2013): 862–69. http://dx.doi.org/10.1002/jat.2901.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Zhang, Chun-yu, Yuan-xi Feng, Yang Yu, Wen-jing Sun, Jing Bai, Feng Chen e Song-bin Fu. "The Molecular Mechanism of Resistance to Methotrexate in Mouse Methotrexate-Resistant Cells by Cancer Drug Resistance and Metabolism SuperArray". Basic Clinical Pharmacology Toxicology 99, n.º 2 (agosto de 2006): 141–45. http://dx.doi.org/10.1111/j.1742-7843.2006.pto_470.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Yuksel, Yasemin, Ramazan Yuksel, Murat Yagmurca, Hacer Haltas, Husamettin Erdamar, Muhsin Toktas e Osman Ozcan. "Effects of quercetin on methotrexate-induced nephrotoxicity in rats". Human & Experimental Toxicology 36, n.º 1 (11 de julho de 2016): 51–61. http://dx.doi.org/10.1177/0960327116637414.

Texto completo da fonte

Resumo:

Objective: This experimental study was conducted to elucidate the possible protective/therapeutic effects of quercetin against methotrexate (Mtx)-induced kidney toxicity with biochemical and histopathological studies. Methods: Twenty-four adult male rats were randomly divided into four groups, as follows: control group (saline intraperitoneally (i.p.), 9 days), Mtx group (20 mg/kg i.p., single dose), Mtx + quercetin group (50 mg/kg quercetin was orally administered 2 days before and 6 days after Mtx administration) and only quercetin group (50 mg/kg oral, 9 days). Structural changes were evaluated by hematoxylin–eosin and periodic acid–Schiff stainings. Apoptotic changes were investigated by terminal deoxynucleotidyl transferase dUTP nick end labeling assay and caspase-3 antibody. Superoxide dismutase (SOD) and malondialdehyde (MDA) levels were measured in tissue and plasma samples. Results: Mtx compared with the control group, there was significant increase in nephrotoxic tissue damage findings, in addition to apoptotic index (APOI) and caspase-3 expression ( p < 0.05). Mtx + quercetin group revealed significantly lower histopathological damage and APOI and caspase-3 expression decreased when compared to Mtx group. MDA levels were increased in Mtx group compared to others, and by the use of quercetin, this increase was significantly reduced. SOD levels were higher in Mtx group than others. This increase was evaluated as a relative increase arising from oxidative damage caused by Mtx. Conclusion: As a result, Mtx administration may involve oxidative stress by causing structural and functional damage in kidney tissue in rats. Quercetin reduced the Mtx-induced oxidative stress through its antioxidant properties and so quercetin may be promising to alleviate Mtx-induced renal toxicity.

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Nolte, H., e P. Stahl Skov. "Inhibition of basophil histamine release by methotrexate". Agents and Actions 23, n.º 3-4 (maio de 1988): 173–76. http://dx.doi.org/10.1007/bf02142532.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Venkatesan Kotteeswaran, Vidhyutha Srivathsan, Mahima Bhandari, Juanit Thomas E e Trishita Bhattacharya. "Characterization of Methotrexate Loaded Fucoidan/Chitosan Nanoparticles". International Journal of Research in Pharmaceutical Sciences 11, SPL4 (21 de dezembro de 2020): 2644–54. http://dx.doi.org/10.26452/ijrps.v11ispl4.4534.

Texto completo da fonte

Resumo:

Methotrexate is one of the most popular and safe anti-inflammatory drugs which is an antifolate-type antimetabolite and is used as an anticancer drug. In this study, oppositely charged chitosan and fucoidan have been non-covalently bonded using their electrostatic interactions with the methotrexate drug loaded into these nanoparticles. Fucoidan is obtained from marine algae which are composed of l-fucose and sulfate groups in various types of brown seaweeds; whereas chitosan is a naturally occurring biopolymer obtained through the N-deacetylation of chitin. Depending on the fucoidan / chitosan (F / C) weight ratio, three distinct nanoparticles (1F / 1C; 3F / 1C; 5F / 1C) are synthesized and characterized. Nanoparticles were prepared using cross linkers EDC and NHS at a constant pH to reduce the conjugate size. The prepared conjugates were characterized for their size and zeta potential using DLS analysis and the functional groups were analysed using FTIR. DLS results proclaimed that there was size reduction in particle size with cross linker and without the drug methotrexate. The 5:1 F/C nanoparticles was seen to be 441.5 nm, the difference being considerable larger in the 5:1 formulation. Hence for further analysis 5:1 F/C nanoparticles were preferred. Maximum entrapment efficiency was observed in 5:1 F/C nanoparticle with and without cross linkers. To understand the structural morphology of nanoparticles electromagnetic magnification like SEM and TEM were taken in account.

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Weitman, Steven D., Gregory J. Kato, Jerry L. Barbosa e Barton A. Kamen. "Low-dose methotrexate therapy for hepatoblastoma". Cancer Chemotherapy and Pharmacology 28, n.º 3 (1991): 233–34. http://dx.doi.org/10.1007/bf00685519.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Çetiner, Mustafa, Göksel Şener, A. Özer Şehirli, Emel Ekşioğlu-Demiralp, Feriha Ercan, Serap Şirvancı, Nursal Gedik, Sertaç Akpulat, Tülay Tecimer e Berrak Ç. Yeğen. "Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death". Toxicology and Applied Pharmacology 209, n.º 1 (novembro de 2005): 39–50. http://dx.doi.org/10.1016/j.taap.2005.03.009.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Ibsen, Hans Henning W. "Electroencephalographic Examination in Seven Patients Treated with Methotrexate for Psoriasis". Acta Pharmacologica et Toxicologica 58, n.º 4 (13 de março de 2009): 303–4. http://dx.doi.org/10.1111/j.1600-0773.1986.tb00113.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Mouridsen, H. T., E. Jacobsen e O. Faber. "The Pharmacokinetics of Cyclophosphamide in Man Following Treatment with Methotrexate". Acta Pharmacologica et Toxicologica 38, n.º 5 (13 de março de 2009): 508–12. http://dx.doi.org/10.1111/j.1600-0773.1976.tb03146.x.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

David, N. Bailey, Joseph J. Coffee e R. Briggs John. "Percutaneous absorption of methotrexate as its sodium salt in vivo". Journal of Toxicology: Cutaneous and Ocular Toxicology 6, n.º 1 (janeiro de 1987): 9–12. http://dx.doi.org/10.3109/15569528709052159.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Koçak, Aslıhan Yonca, Oğuzhan Koçak, Figen Aslan e Mustafa Tektaş. "Methotrexate toxicity presenting as cutaneous ulcerations on psoriatic plaques". Cutaneous and Ocular Toxicology 32, n.º 4 (28 de março de 2013): 333–35. http://dx.doi.org/10.3109/15569527.2013.779278.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!